- Home
- TCRT vs OGEN Comparison
TCRT vs OGEN Comparison
Compare TCRT & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- OGEN
- Stock Information
- Founded
- TCRT 1998
- OGEN 1996
- Country
- TCRT United States
- OGEN United States
- Employees
- TCRT N/A
- OGEN N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- OGEN Health Care
- Exchange
- TCRT Nasdaq
- OGEN Nasdaq
- Market Cap
- TCRT 3.8M
- OGEN 4.6M
- IPO Year
- TCRT N/A
- OGEN N/A
- Fundamental
- Price
- TCRT $3.03
- OGEN $4.28
- Analyst Decision
- TCRT
- OGEN
- Analyst Count
- TCRT 0
- OGEN 0
- Target Price
- TCRT N/A
- OGEN N/A
- AVG Volume (30 Days)
- TCRT 12.3K
- OGEN 599.0K
- Earning Date
- TCRT 05-15-2025
- OGEN 05-09-2025
- Dividend Yield
- TCRT N/A
- OGEN N/A
- EPS Growth
- TCRT N/A
- OGEN N/A
- EPS
- TCRT N/A
- OGEN N/A
- Revenue
- TCRT $11,000.00
- OGEN N/A
- Revenue This Year
- TCRT $5,680,500.00
- OGEN N/A
- Revenue Next Year
- TCRT N/A
- OGEN N/A
- P/E Ratio
- TCRT N/A
- OGEN N/A
- Revenue Growth
- TCRT 83.33
- OGEN N/A
- 52 Week Low
- TCRT $1.31
- OGEN $3.12
- 52 Week High
- TCRT $11.00
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- TCRT 60.98
- OGEN 43.10
- Support Level
- TCRT $2.50
- OGEN $3.12
- Resistance Level
- TCRT $2.80
- OGEN $9.60
- Average True Range (ATR)
- TCRT 0.21
- OGEN 1.04
- MACD
- TCRT 0.01
- OGEN -0.12
- Stochastic Oscillator
- TCRT 98.31
- OGEN 17.90
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.